Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy

Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present results a clinical study on prophylaxis cisplatin-induced patients with peritoneal carcinomatosis undergoing cytoreduction hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin). Prophylaxis was imipenem/cilastatin. Cilastatin selective inhibitor renal dehydropeptidase I proximal tubule cells that can reduce cisplatin. Unfortunately, cilastatin not currently marketed alone, only be administered combination imipenem. The has retrospective part serves as control (n = 99 receiving standard surgical prophylaxis) prospective imipenem/cilastatin corresponding to group 85 patients). In both groups, we collected specific data preoperative risk factors damage, fluid management, hemodynamic control, urine volume during surgery (including perfusion), well function first seven days after surgery. main finding may exert nephroprotective effect cisplatin perfusion. Creatinine values remained lower than (ANOVA test, p 0.037). This translates into easier management these postoperative period, significantly shorter intensive care unit (ICU) hospital stay.